Loading…
Develops oligonucleotide therapies delivered directly to muscle tissue for muscular dystrophies and myotonic dystrophy.
Develops oligonucleotide therapies delivered directly to muscle tissue for muscular dystrophies and myotonic dystrophy.
Has no product on the market, so operations are funded by selling shares to investors, and each trial result sets how easily it can raise more money. Any later income would come from selling approved therapies itself or through partners.
Moat: narrow (IP / patents, process know-how). Proprietary FORCE muscle-targeting delivery platform for oligonucleotides, though still clinical-stage.
Headquarters: Waltham, Massachusetts, US · Founded: 2017 · Employees: 258
Size Dyne Therapeutics (DYN) is a United States Health Care company (Biotechnology) with a market value of $3.37B, the 1466th largest of 3,117 United States companies the cockpit tracks. Shares closed at $18.07 on 6 Nov 2026.
Performance Over six months the shares gained 2.6%, against +9.2% for the median peer and -1.1% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.
Short interest Short interest is 13.6% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$2.17M | -$2.05M | -$2.24M | -$2.46M | -$3.35M |
| EBITDA | -$535M | -$466M | -$342M | -$240M | -$168M |
| Net income | -$519M | -$446M | -$317M | -$236M | -$168M |
| Free cash flow | -$499M | -$424M | -$295M | -$189M | -$157M |
| Capital expenditure | $21.4M | $20.7M | $2.38M | $729,000 | $3.07M |
| Total debt | $233M | $169M | $24.0M | $27.4M | $30.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Dyne Therapeutics DYN | $3.37B | +3% | n/a | n/a | n/a | n/a |
| Sarepta Therapeutics SRPT | $1.88B | -11% | -20% | -3% | 1.1× | 11.9% |
| Ionis Pharmaceuticals IONS | $6.55B | -48% | -7% | -68% | 7.7× | n/a |
| Wave Life Sciences WVE | $664M | -53% | -35% | -321% | 3.9× | n/a |
| Entrada Therapeutics TRDA | n/a | -29% | n/a | n/a | n/a | n/a |
| Solid Biosciences SLDB | $707M | -9% | n/a | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | $1.43B | -30% | +12% | 19% | 0.9× | -17.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DYN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.4% | +0.4% | 6th highest of 21 |
| 6-month return | +2.6% | +9.2% | 10th lowest of 21 |
| Distance from 52-week high | -33.8% | -24.0% | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dyne Therapeutics DYN | United States | $3.37B | +3% | n/a | n/a | n/a | n/a | n/a |
| Virbac VIRP.PA | France | $3.38B | +5% | +4% | 15% | 2.1× | 6.2% | +9.4% |
| Hualan Biological Engineering 002007.SZ | China | $3.37B | -15% | -11% | 17% | 5.6× | 16.7% | -1.8% |
| XtalPi 2228.HK | Hong Kong | $3.35B | -34% | +4% | -127% | 26.3× | n/a | n/a |
| Disc Medicine IRON | United States | $3.50B | +16% | n/a | n/a | n/a | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 3.9× | n/a | n/a |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | 128.0× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.62B | +21% | n/a | n/a | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.63B | -7% | +121% | -253% | 49.1× | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | 10.4× | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | 45.9× | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 4.8× | 3.2% | +12.5% |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | 6,237.3× | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | 51.7× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 2.8× | -2.0% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | 5.5× | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.91B | +74% | +37% | 21% | 14.2× | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.85B | -9% | +20% | -3% | 6.1× | n/a | n/a |
| ADMA Biologics ADMA | United States | $2.85B | +56% | +8% | 42% | 5.7× | -0.8% | +64.6% |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | 308.8× | n/a | n/a |